Suzhou Porton Biologics Ltd, a China-based contract development and manufacturing organization (CDMO), announced the completion of a Series B financing round totaling RMB 520 million (USD 76.1 million). The round was led by China Merchants Health Industry Holding Co., Ltd, with participation from CMS Capital, China Merchants Security, Fosun Health Fund, Guangdong Mintou Private Equity Fund, SDIC Taikang Trust, SDIC CMS Management, HM Capital, Huashan Ruilian Fund Management, and MV Venture.
Funding Details
Proceeds from the Series B round will support Porton’s global expansion, the construction of a commercialization manufacturing plant, and the enhancement of its end-to-end gene and cell therapy (GCT) CDMO platform.
Company Profile
Founded in 2018, Porton offers a comprehensive GCT CDMO service platform covering plasmids, cell therapy, gene therapy, oncolytic virus, nucleic acid therapy, and live bacterial therapy. The company’s 16,000-square-meter industrialization plant is expected to commence operations in Q4 2023.
Strategic Outlook
Porton plans to strengthen its capabilities in AAV, oncolytic virus, and mRNA platforms, increase production capacity for GMP plasmid, virus, and cell therapy products, and advance the GCT industry through its enhanced CDMO platform.-Fineline Info & Tech
